FDA grants de novo for the HemoSonics’ Quantra System

Back to list

March 13, 2019 : Stago is proud to announce that HemoSonics, a Stago Group company, has been granted de novo marketing authorization by the FDA for its revolutionary diagnostic device Quantra Hemostasis Analyzer platform, and its initial QPlus cartridge. The system is now commercially available in the USA.

For more information: click on Opens external link in current windowhere